GGrantIndex
← Leaderboards

Raju C Reddy

Veterans Health Administration

$6,243,629
Attributed
$6,243,629
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $924.7K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,243,629 · 5
VA$0 · 2

By mechanism

R01$5,212,462 · 3
K08$663,290 · 1
R21$367,877 · 1
I01$0 · 2

Top collaborators

No co-investigators on record.

Most similar at Veterans Health Administration

Same institution · by research overlap

Others in their field

Top investigators on “Inflammation

Research focus

InflammationIn VivoIn VitroLungMediatingAgonistKnock-OutResponseAnti-Inflammatory AgentsCytokineEpithelial CellsNovel TherapeuticsSeveritiesAdverse EffectsAnti-InflammatoryTranscription FactorInflammatory ResponseFunctional DisorderNuclear Hormone ReceptorsPeroxisome Proliferator-Activated ReceptorsInflammatoryMouse ModelNuclearValidation

Grant awards (31)

Nur77: Novel Mechanistic Insights and Activation in COPD$0
I01 · FY2025 · VA · contact PI
Nur77: Novel Mechanistic Insights and Activation in COPD$0
I01 · FY2024 · VA · contact PI
Nur77: Novel Mechanistic Insights and Activation in COPD$0
I01 · FY2023 · VA · contact PI
Nur77: Novel Mechanistic Insights and Activation in COPD$0
I01 · FY2022 · VA · contact PI
PPAR-delta as a Novel Therapeutic Target in Asthma$391,250
R01 · FY2020 · AI · contact PI
PPAR-delta as a Novel Therapeutic Target in Asthma$391,250
R01 · FY2019 · AI · contact PI
Airway Epithelial Cell Farnesoid X Receptor in COPD Pathophysiology$391,250
R01 · FY2019 · HL · contact PI
PPAR-delta as a Novel Therapeutic Target in Asthma$476,694
R01 · FY2018 · AI · contact PI
Airway Epithelial Cell Farnesoid X Receptor in COPD Pathophysiology$391,250
R01 · FY2018 · HL · contact PI
PPAR-delta as a Novel Therapeutic Target in Asthma$504,756
R01 · FY2017 · AI · contact PI
Airway Epithelial Cell Farnesoid X Receptor in COPD Pathophysiology$388,959
R01 · FY2017 · HL · contact PI
PPAR-delta as a Novel Therapeutic Target in Asthma$30,960
R01 · FY2017 · AI · contact PI
PPAR-delta as a Novel Therapeutic Target in Asthma$385,000
R01 · FY2016 · AI · contact PI
Role of PPAR-gamma in Smoking-induced COPD Progression and Steroid Resistance$0
I01 · FY2016 · VA · contact PI
Role of PPAR-gamma in Smoking-induced COPD Progression and Steroid Resistance$0
I01 · FY2015 · VA · contact PI
Role of PPAR-gamma in Smoking-induced COPD Progression and Steroid Resistance$0
I01 · FY2014 · VA · contact PI
Nitrated Fatty Acids, Novel Anti-inflammatory Mediator in Allergic Airway Disease$315,759
R01 · FY2013 · HL · contact PI
Role of PPAR-gamma in Smoking-induced COPD Progression and Steroid Resistance$0
I01 · FY2013 · VA · contact PI
Nitrated Fatty Acids, Novel Anti-inflammatory Mediator in Allergic Airway Disease$319,523
R01 · FY2012 · HL · contact PI
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas$322,750
R01 · FY2011 · HL · contact PI
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas$322,750
R01 · FY2010 · HL · contact PI
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas$383,525
R01 · FY2009 · HL · contact PI
Curcumin: A Multi-Mechanism HIV Microbicide$175,323
R21 · FY2009 · AI · contact PI
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas$106,821
R01 · FY2009 · HL · contact PI
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas$89,965
R01 · FY2009 · HL · contact PI
Curcumin: A Multi-Mechanism HIV Microbicide$192,554
R21 · FY2008 · AI · contact PI
PPARGamma in Sepsis-Induced Immunosuppression$132,658
K08 · FY2006 · HL · contact PI
PPARGamma in Sepsis-Induced Immunosuppression$132,658
K08 · FY2005 · HL
PPARGamma in Sepsis-Induced Immunosuppression$132,658
K08 · FY2004 · HL
PPARGamma in Sepsis-Induced Immunosuppression$132,658
K08 · FY2003 · HL
PPARGamma in Sepsis-Induced Immunosuppression$132,658
K08 · FY2002 · HL